Recruitment unclearEUCTR 2021-001337-40

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO DETERMINE EFFICACY AND SAFETY OF BXCL501 IN AGITATION ASSOCIATED WITH PEDIATRIC SCHIZOPHRENIA AND Bipolarity

This historical record does not confirm current site availability.

Historical research recordSpain

The study in practice

Understand this study

What is this study about?

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.

Listed locations: Spain
Study phase: Phase 1

What to know before participating

A point to clarify

This is historical registry information. What is the current study status and protocol?

Study clarity

Things to check before joining

Study start dateNot clearly listed

Recruitment status: Recruitment unclear
Enrollment listed in the registry: 120
Sponsor: BioXcel Therapeutics, Inc.
Sponsor type: Biotech company
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 1
Locations: Spain
Age range: Not clearly listed
Official registry ID: EUCTR 2021-001337-40
Official title: Show the full official title
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO DETERMINE EFFICACY AND SAFETY OF BXCL501 IN AGITATION ASSOCIATED WITH PEDIATRIC SCHIZOPHRENIA AND BIPOLAR DISORDER

Get this study by email

Recruitment & locations

Status unknown

Spain

Registry details

Historical country statuses

Spain — Restarted

A listed location does not confirm current availability.

FAQ

Questions about this study

Who is behind this study?

The study sponsor is BioXcel Therapeutics, Inc.

Want to explore more studies?

Explore studies